politics

Some Covid vaccines may be better suited for certain age groups, Novavax scientist says


S

ome Covid vaccines may be “better suited” for certain age groups or for use as booster jabs, a scientist working on the Novavax trial said today.

Professor Paul Heath, Novavax trial chief investigator, said the broad range of jabs being used to help fight the pandemic would help leaders “refine the vaccine programme”.

He said in time some vaccines might turn out to be “better suited” to certain age groups while others might be more appropriate for booster doses.

The scientist made the comments when asked on Sky News why it was important to have lots of different vaccines.

Professor Heath said: “Obviously because there are so many people that need to be vaccinated so we need to have a huge supply of vaccine in order to fully vaccinate our population so that I think is the basic reason.

“There are other things that may be shown between the different vaccines ultimately.

“So it may be shown for example that certain vaccines are more appropriate for certain groups for the elderly, for those with underlying health problems and so on.

“I think in time it may be that we define different groups for different vaccines.”

Professor Heath, who is also director of the Vaccine Institute at St George’s, University of London, added: “We are for example contemplating vaccinating adolescents and children, we are contemplating and indeed vaccinating pregnant women and it may be that studies will show that certain vaccines are perhaps better suited to different groups.

“So to have this range of vaccines using a range of different technologies available allows us to ultimately refine the vaccine programme.

“The next bit of course will be the booster doses.

“We’ve already heard over the weekend a proposal that booster doses will be considered and implemented potentially later this year and it may be that different vaccines are better suited to be booster doses.

“So again having a whole range of different vaccines using different vaccine technologies allows us to refine the programme that we have at the moment.”



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more